1.61
+0.1(+6.62%)
Currency In USD
| Previous Close | 1.51 |
| Open | 1.58 |
| Day High | 1.72 |
| Day Low | 1.54 |
| 52-Week High | 28.6 |
| 52-Week Low | 1.15 |
| Volume | 205,131 |
| Average Volume | 638,598 |
| Market Cap | 3.25M |
| PE | -0.08 |
| EPS | -19.5 |
| Moving Average 50 Days | 1.73 |
| Moving Average 200 Days | 6.09 |
| Change | 0.1 |
If you invested $1000 in Artelo Biosciences, Inc. (ARTL) since IPO date, it would be worth $3.85 as of January 15, 2026 at a share price of $1.61. Whereas If you bought $1000 worth of Artelo Biosciences, Inc. (ARTL) shares 5 years ago, it would be worth $18.44 as of January 15, 2026 at a share price of $1.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate
GlobeNewswire Inc.
Dec 23, 2025 2:00 PM GMT
SOLANA BEACH, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people liv
Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models
GlobeNewswire Inc.
Dec 03, 2025 1:30 PM GMT
Findings further validate FABP5 inhibition and strengthen the therapeutic potential of Artelo’s FABP5 platform for mood and stress-related disordersSOLANA BEACH, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Ar
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results
GlobeNewswire Inc.
Nov 12, 2025 1:00 PM GMT
Encouraging Clinical Progress, Including Positive Interim Phase 2 Results for the Treatment of Cancer Anorexia Cachexia SyndromeSOLANA BEACH, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharma